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A new challenge to public health has recently emerged from
potent and untested drugs being sold under the guise of “dietary”
supplements.1-4 Fuelled by growing demand for products
promising a better body, enhanced performance, and increased
wellbeing, this trend highlights creative marketing strategies
used in the illicit supply of drugs.
Nine supplements suspected of containing drugs were analysed
as part of an investigation for the television programme Spotlight
(broadcasted 31 March 2015 by BBC Northern Ireland). The
supplements were bought from high street shops and from an
e-commerce site (box). Products were sold as “fat burners” or
“pro-hormones,” with packaging often blatantly listing chemical
names of drugs.
Ostarine, found in product 4, is a selective androgen receptor
modulator that is being tested as a medicine, but has not been
authorised for marketing. The stimulant 1,3-dimethylamylamine
(DMAA) was found in products 1 and 2, and
1,3-dimethylbutylamine (DMBA) was found in products 3 and
8. DMAAwas recently identified in “dietary supplements” and
has been associated with adverse events, including acute
myocardial infarction, strokes, and deaths.4 Since regulators
removed DMAA from the market, an analogue DMBA has
appeared as a replacement.3 Products 6, 7, and 9 contained
anabolic steroids, some of which have been associated with
hepatoxicity.2 Although advertised as legal pro-hormones they
are controlled drugs in the UK.
These findings illustrate market developments, which now
include dietary supplements containingmedicines, “legal highs,”
and controlled drugs. Many experienced users are aware of this
marketing strategy. However, young and inexperienced people
may be unknowingly exposing themselves to potent drugs.
Clinicians should ask patients about the use of supplements and
report suspected adverse events to medicine agencies.
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Content of nine dietary supplements bought on the high street and internet
Product 1. Strip Ts*: Caffeine, 1,3-dimethylamylamine (DMAA), synephrine
Product 2. Strip Ts*: Caffeine, (DMAA), synephrine
Product 3. Angel Dust: Caffeine, 1,3-dimethylbutylamine (DMBA)
Product 4. Ostapure: Ostarine
Product 5. Hemo Rage: Caffeine, synephrine
Product 6. SD Extreme: methasterone
Product 7. Metha-Quad Extreme: Methylstenbolone, methasterone, 13-ethyl-3 methoxy-gona-2,5(10)-dien-17-one
Product 8. Mutant Noxx Mass Power Blend: Caffeine, DMBA
Product 9. M1T Hulk XT: Methyl-1-testosterone
*Same product bought from two different shops.
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